A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

By sjmartinez • February 15, 2024

Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussein M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. Future Oncol. 2024 Feb 15. doi: 10.2217/fon-2023-0859. Epub ahead of print. PMID: 38357801.

Tags: encorafenib plus binimetinib, Hematology/Oncology, Non-small cell lung cancer, PHAROS, plain language summary

Early cellular events of osteomucosal healing in the tooth extraction socket

Kim S, Song M, Williams D, Du W, Cho I, Bae E, Kim J, Goswami A, Shin KH, Park NH, Kim RH. Early cellular events[...]

A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer

Cummings AL, Sussell J, Rosettie KL, Moustaid FE, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A treatment-impact model of alectinib for the[...]

A novel application of LC-MS/MS accurately quantifies the labile redox pools of cellular coenzymes Q9 and Q10

Jain A, Li VW, Salem J, Reddy ST, Palaskas NJ, Meriwether D. A novel application of LC-MS/MS accurately quantifies the labile redox pools of cellular[...]